UK approves Europe’s first weight-loss pill: Who qualifies, how it works, and NHS availability
Key Points
- The MHRA has authorised orforglipron (Foundayo), the first GLP-1 tablet approved in Europe for weight management and type 2 diabetes.
- Eligibility covers adults with a BMI of 30 or above, or 27 to 30 with a weight-related health condition.
- The dose starts at 0.8 mg once daily and escalates in six steps to 17.2 mg, with a month minimum at each level.
- Common side effects include nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain.
- The NHS does not fund the drug yet; NICE evaluation comes next.
The Medicines and Healthcare products Regulatory Agency has authorised orforglipron, a once-daily weight-loss tablet, making the UK the first country in Europe to approve a GLP-1 pill for weight management and type 2 diabetes.
The approval, granted to Eli Lilly on Monday (10 August), covers adults with a body mass index of 30 or above, and adults with a BMI between 27 and 30 who also have at least one weight-related health condition.
Patients take the tablet, sold as Foundayo, alongside a reduced-calorie diet and increased physical activity.
The MHRA has also cleared orforglipron to improve glycaemic control in patients whose type 2 diabetes is insufficiently controlled.
“Following rigorous assessment of orforglipron’s safety, quality, and effectiveness, we are pleased to be the first regulator in Europe to authorise this tablet for weight management and type 2 diabetes,” said Julian Beach, MHRA Executive Director of Healthcare Quality and Access.
“As with all GLP-1 receptor agonists, this is a prescription-only medication, and the MHRA will keep the safety and effectiveness of orforglipron under close review.”
Patients take one tablet a day at any time, with no food or water restrictions. Treatment starts at 0.8 mg and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with a minimum of one month at each dose level. The MHRA directs patients to follow the instructions in the Patient Information Leaflet.
How the tablet works
Orforglipron mimics glucagon-like peptide-1, a hormone the body releases after eating. It acts on the areas of the brain that regulate appetite, helping people feel fuller for longer, reducing hunger and decreasing food cravings, which supports weight reduction alongside diet and lifestyle changes. In people with type 2 diabetes it also lowers blood sugar levels when those levels are high.
The most common side effects are nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain. Anyone who suspects a side effect should speak to their doctor, pharmacist or nurse and report it to the Yellow Card scheme through the MHRA website or the Yellow Card app.
NHS availability
The NHS does not currently fund orforglipron. Decisions on NHS use follow established processes, including an evaluation by the National Institute for Health and Care Excellence.
All GLP-1 medicines are prescription-only, and patients can obtain them only from a registered pharmacy with a prescription from a doctor.
The MHRA warns that buying GLP-1 medicines from unregulated sellers carries serious health risks. UK law also prohibits promoting any prescription-only medication directly to the public.
The Summary of Product Characteristics and Patient Information Leaflet will appear on the MHRA Products website within seven days of approval.
